BriaCell Therapeutics Corp. (BCTX) |
|
7.45 0.28 (3.91%)
|
03-31 16:00 |
|
Open: |
7.3 |
Pre. Close: |
7.17 |
|
High:
|
7.49 |
Low:
|
7.1468 |
|
Volume:
|
158,997 |
Market Cap:
|
116(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:17:03 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 8.87 One year: 10.36 |
| Support: |
Support1: 6.64 Support2: 6.05 |
| Resistance: |
Resistance1: 7.59 Resistance2: 8.87 |
| Pivot: |
7 |
| Moving Average: |
MA(5): 7.16 MA(20): 6.94
MA(100): 6.37 MA(250): 6.38  |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 87.7 %D(3): 80.9 |
| RSI: |
RSI(14): 58.5 |
| 52-week: |
High: 12.09 Low: 4.05 |
| Average Vol(K): |
3-Month: 206 (K) 10-Days: 82 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BCTX ] has closed Bollinger Bands are 49.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
7.45 - 7.48 |
7.48 - 7.5 |
|
Low:
|
6.73 - 6.76 |
6.76 - 6.79 |
|
Close:
|
7.12 - 7.17 |
7.17 - 7.21 |
|
Company Description |
|
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada. |
Headline News |
Fri, 31 Mar 2023
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy - Investing News Network
Thu, 30 Mar 2023
BriaCell plans spin-out of pre-clinical assets into new entity (BCTX) - Seeking Alpha
Thu, 30 Mar 2023
BriaCell Therapeutics (BCTX) to Spin-Out Certain Pre-Clinical ... - StreetInsider.com
Fri, 24 Mar 2023
Evolution of Oncology Treatments Giving New Hope to Those ... - PR Newswire
Tue, 21 Mar 2023
FDA’s Wave of Fast Track Designations Pushing Momentum in Healthcare Sector in 2023 - Baystreet.ca
Wed, 15 Mar 2023
BriaCell to Present Clinical and Survival Data in Advanced ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
16 (M) |
| Shares Float |
11 (M) |
|
% Held by Insiders
|
23.7 (%) |
|
% Held by Institutions
|
17.2 (%) |
|
Shares Short
|
1,600 (K) |
|
Shares Short P.Month
|
1,510 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-0.08 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-28.7 |
|
Return on Equity (ttm)
|
-111.4 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.23 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-16 (M) |
|
Levered Free Cash Flow
|
-12 (M) |
Stock Valuations |
|
PE Ratio
|
745 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-93.13 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-7.4 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-01-01 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
